NCT04168502
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04168502 |
| Title | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST